Literature DB >> 14635037

CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages.

Roger H Brookes1, Ansar A Pathan, Helen McShane, Meike Hensmann, David A Price, Adrian V S Hill.   

Abstract

Animal models of tuberculosis point to a protective role for MHC class I-restricted CD8(+) T cells, yet it is unclear how these cells protect or whether such findings extend to humans. Here we report that macrophages infected with Mycobacterium tuberculosis, rapidly process and present an early secreted antigenic target (ESAT-6)-specific HLA class I-restricted CD8(+) T cell epitope. When cocultured with CD8(+) T cells restricted through classical HLA class I molecules the growth of bacilli within macrophages is significantly impaired after 7 days. This slow antimycobacterial activity did not correlate with macrophage lysis but required cell contact. We also found that inhibitors of apoptosis either had no effect or augmented the CD8-mediated suppressive activity, suggesting that an activation signal might be involved. Indeed we show that CD8(+) T cells were able to activate macrophages through receptors that include CD95 (Fas). Consistent with these findings the CD8-mediated suppression of mycobacterial growth was partially reversed by Fas blockade. These data identify a previously unrecognized CD8(+) T cell-mediated mechanism used to control an intracellular infection of macrophages.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14635037     DOI: 10.1002/eji.200324109

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

Review 1.  Evasion and subversion of antigen presentation by Mycobacterium tuberculosis.

Authors:  A Baena; S A Porcelli
Journal:  Tissue Antigens       Date:  2009-06-25

Review 2.  Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy?

Authors:  Samuel M Behar; Maziar Divangahi; Heinz G Remold
Journal:  Nat Rev Microbiol       Date:  2010-08-02       Impact factor: 60.633

3.  Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis.

Authors:  Maziar Divangahi; Danielle Desjardins; Cláudio Nunes-Alves; Heinz G Remold; Samuel M Behar
Journal:  Nat Immunol       Date:  2010-07-11       Impact factor: 25.606

4.  Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts.

Authors:  Claudia Carranza; Esmeralda Juárez; Martha Torres; Jerrold J Ellner; Eduardo Sada; Stephan K Schwander
Journal:  Am J Respir Crit Care Med       Date:  2005-10-06       Impact factor: 21.405

5.  Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 T cell epitopes.

Authors:  A S Hammond; M R Klein; T Corrah; A Fox; A Jaye; K P McAdam; R H Brookes
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

6.  Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting.

Authors:  Hee-Won Moon; Rajiv L Gaur; Sara Shu-Hwa Tien; Mary Spangler; Madhukar Pai; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2017-03-15       Impact factor: 5.948

Review 7.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

8.  Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection.

Authors:  Ying Wu; Joshua S Woodworth; Daniel S Shin; Sheldon Morris; Samuel M Behar
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

9.  Prokaryotic expression and functional analysis of the Mb1514 gene in Mycobacterium bovis.

Authors:  Xiaomin Yin; Xiangmei Zhou; Zhixin Xue; Lihong Tian; Yang Zhou; Lifeng Yang; Deming Zhao
Journal:  Mol Cell Biochem       Date:  2013-10-20       Impact factor: 3.396

Review 10.  Antigen-specific CD8(+) T cells and protective immunity to tuberculosis.

Authors:  Samuel M Behar
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.